Skip to main content
SpringerLink
Log in

Dementia

  • Chapter
  • First Online:
Drug Therapy for the Elderly

  • 1945 Accesses

Abstract

Dementia is a clinical syndrome characterized by various symptoms, such as memory and concentration difficulties, behavioral abnormalities, language and perception difficulties, as well as problems with the ability of comprehension and judgment.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P (2003) Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 60:387–392

    Article  PubMed  Google Scholar 

  • Aarsland D, Ballard C, Walker Z et al (2009) Memantine in patients with Parkinson’s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol 8:613–618

    Article  PubMed  CAS  Google Scholar 

  • Adler G, Teufel M, Drach LM (2003) Pharmacological treatment of frontotemporal dementia: treatment response to the MAO-A inhibitor moclobemide. Int J Geriatr Psychiatry 18:653–655

    Article  PubMed  Google Scholar 

  • Andersen-Ranberg K, Vasegaard L, Jeune B (2001) Dementia is not inevitable: a population-based study of Danish centenarians. J Gerontol B Psychol Sci Soc Sci 56:152–159

    Article  Google Scholar 

  • Atri A, Shaughnessy LW, Locascio JJ, Growdon JH (2008) Longterm course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis Assoc Disord 22:209–221

    Article  PubMed  CAS  Google Scholar 

  • Ballard C, Hanney ML, Theodoulou M et al (2009) The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol 8:151–157

    Article  PubMed  CAS  Google Scholar 

  • Ballard C, Gauthier S, Corbett C, Aarsland D, Jones E (2011) Alzheimer’s disease. Lancet 377:1019–1031

    Article  PubMed  Google Scholar 

  • Banerjee S, Hellier J, Dewey M et al (2011) Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. Lancet 378:403–411

    Article  PubMed  CAS  Google Scholar 

  • Bowler JV (2005) Vascular cognitive impairment. J Neurol Neurosurg Psychiatry 76(Suppl 5):v35–v44

    Article  PubMed  Google Scholar 

  • Boyle PA, Malloy PF (2004) Treating apathy in Alzheimer’s disease. Dement Geriatr Cogn Disord 17:91–99

    Article  PubMed  Google Scholar 

  • Burns A, Bernabei R, Bullock R et al (2009) Safety and efficacy of galantamine (reminyl) in severe Alzheimer’s disease (the SERAD study): a randomized, placebo-controlled, double blind trial. Lancet Neurol 8:39–47

    Article  PubMed  CAS  Google Scholar 

  • Buscemi N, Vandermeer B, Hooton N et al (2006) Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: meta-analysis. BMJ 332:385–393

    Article  PubMed  CAS  Google Scholar 

  • Camicioli R, Fisher N (2004) Progress in clinical neurosciences: Parkinson’s disease with dementia and dementia with Lewy bodies. Can J Neurol Sci 31:7–21

    PubMed  Google Scholar 

  • Cardinali DP, Brusco LI, Liberczuk C, Furio AM (2002) The use of melatonin in Alzheimer’s disease. Neuro Endocrinol Lett 23(Suppl 1):20–23

    PubMed  CAS  Google Scholar 

  • Craig D, Birks J (2005) Rivastigmine for vascular cognitive impairment. Cochrane Database Syst Rev 2:CD004744

    PubMed  Google Scholar 

  • Craig D, Birks J (2006) Galantamine for vascular cognitive impairment. Cochrane Database Syst Rev 1:CD004746

    PubMed  Google Scholar 

  • Cummings J, Jones R, Wilkinson D et al (2010) Effect of donepezil on cognition in severe Alzheimer’s disease: a pooled data analysis. J Alzheimers Dis 21:843–851

    PubMed  CAS  Google Scholar 

  • Davies NM, Kehoe PG, Ben-Shlomo Y, Martin YM (2011) Association of anti-hypertensive treatments with Alzheimer’s disease, vascular dementia, and other dementias. J Alzheimers Dis 26:699–708

    PubMed  Google Scholar 

  • Doody RS, Geldmacher DS, Gordon B et al (2001) Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer’s disease. Arch Neurol 58:427–433

    Article  PubMed  CAS  Google Scholar 

  • Emre M, Aarsland D, Albanese A et al (2004) Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med 351:2509–2518

    Article  PubMed  CAS  Google Scholar 

  • Emre M, Tsolaki M, Bonuccelli U et al (2010) Memantine for patients with Parkinson’s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 9:969–977

    Article  PubMed  CAS  Google Scholar 

  • European Medicines Agency (2009) Committee for medicinal products for human use. Guidelines on medicinal products for the treatment of Alzheimer’s disease and other dementias. http://www.ema.europa.eu/pdfs/human/ewp/055395en.pdf. Accessed 11 Jan 2010

  • Ferri CP, Prince M, Brayne C et al (2005) Global prevalence of dementia: a Delphi consensus study. Lancet 366:2112–2117

    Article  PubMed  Google Scholar 

  • Fuchs GA, Gemende I, Herting B et al (2004) Dementia in idiopathic Parkinson’s syndrome. J Neurol 251(Suppl 6):VI/28–VI/32

    Google Scholar 

  • Gardette V, Andieu S, Lapeyre-Mestre M et al (2010) Predictive factors of discontinuation and switch of choline esterase inhibitors in community-dwelling patients with Alzheimer’s disease: a 2-year prospective, multicentre, cohort study. CNS Drugs 24:431–442

    Article  PubMed  CAS  Google Scholar 

  • Getsios D, Blume S, Ishak KJ et al (2010) Cost effectiveness of donepezil in the treatment of mild to moderate Alzheimer’s disease: a U.K. evaluation using discrete-event simulation. Pharmacoeconomics 28:411–427

    Article  PubMed  Google Scholar 

  • Hansen RA, Gartlehner G, Webb AP et al (2008) Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: a systematic review and meta-analysis. Clin Interv Aging 3:211–225

    PubMed  CAS  Google Scholar 

  • Herrmann N, Lanctot KL (2005) Do atypical antipsychotics cause stroke? CNS Drugs 19:91–103

    Article  PubMed  Google Scholar 

  • Hogan DB (2006) Donepezil for severe Alzheimer’s disease. Lancet 367:1031–1032

    Article  PubMed  Google Scholar 

  • Hogan DB, Patterson C (2002) Progress in clinical neurosciences: treatment of Alzheimer’s disease and other dementias—review and comparison of the cholinesterase inhibitors. Can J Neurol Sci 29:306–314

    PubMed  Google Scholar 

  • Hogan DB, Goldlist B, Naglie G, Patterson C (2004) Comparison studies of cholinesterase inhibitors for Alzheimer’s disease. Lancet Neurol 3:622–626

    Article  PubMed  CAS  Google Scholar 

  • Kavirajan H, Schneider LS (2007) Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol 6:782–792

    Article  PubMed  CAS  Google Scholar 

  • Kiencke P, Daniel D, Grimm C, Rychlik R (2011) Direct costs of Alzheimer’s disease in Germany. Eur J Health Econ 12:533–539

    Article  PubMed  Google Scholar 

  • Lobo A, Launer LJ, Fratiglioni L et al (2000) Prevalence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic diseases in the elderly research group. Neurology 54:S4–S9

    Article  PubMed  CAS  Google Scholar 

  • Lopez OL, Becker JT, Wahed AS et al (2009) Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry 80:600–607

    Article  PubMed  CAS  Google Scholar 

  • Maidment I, Fox C, Boustani M (2006) Cholinesterase inhibitors for Parkinson’s disease dementia. Cochrane Database Syst Rev 1:004747

    Google Scholar 

  • McKeith IG, Dickson DW, Lowe J et al (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65:1863–1872

    Article  PubMed  CAS  Google Scholar 

  • Neary D, Snowden J, Mann D (2005) Frontotemporal dementia. Lancet Neurol 4:771–780

    Article  PubMed  Google Scholar 

  • Ott A, Breteler MM, van Harskamp F, Stijnen T, Hofman A (1998) Incidence and risk of dementia. The Rotterdam Study. Am J Epidemiol 147:574–580

    Article  PubMed  CAS  Google Scholar 

  • Reitz C, Brayne C, Mayeux R (2011) Epidemiology of Alzheimer disease. Nat Rev Neurol 7:137–152

    Article  PubMed  Google Scholar 

  • Roman GC, Salloway S, Black SE et al (2010) Randomized, placebo-controlled, clinical trial of donepezil in vascular dementia: differential effects by hippocampal size. Stroke 41:1213–1321

    Article  PubMed  CAS  Google Scholar 

  • Samuel W, Caligiuri M, Galasko D et al (2000) Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study. Int J Geriatr Psychiatry 15:794–802

    Article  PubMed  CAS  Google Scholar 

  • Schneider LS, Dagerman K, Insel PS (2006) Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 14:191–210

    Article  PubMed  Google Scholar 

  • Schneider LS, Dagerman KS, Higgins JP, McShane R (2011) Lack of evidence for the efficacy of memantine in mild Alzheimer disease. Arch Neurol 68:991–998

    Article  PubMed  Google Scholar 

  • Snitz BE, O’Meara ES, Carlson MC, Ginkgo Evaluation of Memory (GEM) Study Investigators et al (2009) Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial. JAMA 302:2663–2670

    Article  PubMed  CAS  Google Scholar 

  • Tariot PN, Farlow MR, Grossberg GT et al (2004) Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 291:317–324

    Article  PubMed  CAS  Google Scholar 

  • Trifiro G, Gambassi G, Sen EF et al (2010) Association of community-acquired pneumonia with antipsychotic drug use in elderly patients: a nested case-control study. Ann Intern Med 152:418–425

    PubMed  Google Scholar 

  • Wehling M, Groth H (2011) Challenges of longevity in developed countries: vascular prevention of dementia as an immediate clue to tackle an upcoming medical, social and economic stretch. Neurodegener Dis 8:275–282

    Article  PubMed  Google Scholar 

  • Winblad B, Kilander L, Eriksson S et al (2006) Donepezil in patients with severe Alzheimer’s disease: double-blind, parallel group, placebo-controlled study. Lancet 367:1057–1065

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Central Institute of Mental Health, Medical Faculty Mannheim/Heidelberg University, Square J 5, 68159, Mannheim, Germany

    Stefan Schwarz & Lutz Frölich

Authors
  1. Stefan Schwarz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lutz Frölich
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stefan Schwarz .

Editor information

Editors and Affiliations

  1. Inst. Klinische Pharmakologie, Klinikum Stadt Mannheim gGmbH, Theodor-Kutzer-Ufer 1-3, Mannheim, 68167, Germany

    Martin Wehling

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag Wien

About this chapter

Cite this chapter

Schwarz, S., Frölich, L. (2013). Dementia. In: Wehling, M. (eds) Drug Therapy for the Elderly. Springer, Vienna. https://doi.org/10.1007/978-3-7091-0912-0_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-0912-0_15

  • Published:

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-7091-0911-3

  • Online ISBN: 978-3-7091-0912-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation